News
Can a new CEO fix Novo Nordisk's problems? This analyst says no.
Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination with Josh Lipton and Bullseye American Ingenuity Fund portfolio manager Adam Johnson to discuss the surprise C-suite change.
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.
For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...
Novo Nordisk has potential with a 27% upside, strong market shares, and high ROI strategies. See why we recommend a buy on ...
The Novo Nordisk Foundation started a dialog with Novo’s board “on the merits of an accelerated CEO succession,” Novo said, ...
CEO Lars Fruergaard Jørgensen is set to step down. Charter (CHTR) and Cox Communications announce a merger in a $34.5 billion deal. Take Two (TTWO) forecasts weak 2026 bookings as the delayed release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback